TY - JOUR AU - Pola, Madhuri AU - Tiwari, Alok AU - Chandrasai, Potla Durthi PY - 2023/05/22 Y2 - 2024/03/29 TI - A Comprehensive Review on Technological Advances in Alternate Drug Discovery Process:Drug Repurposing JF - Current Trends in Biotechnology and Pharmacy JA - CTBP VL - 17 IS - 2 SE - Research Paper DO - 10.5530/ctbp.2023.2.28 UR - https://www.abap.co.in/index.php/home/article/view/875 SP - 907-916 AB - <p style="text-align: justify;">The traditional de novo drug discovery is time consuming, costly and in some instances the drugs will fail to treat the disease which result in a huge loss to the organization. Drug repurposing is an alternative drug discovery process to overcome the limitations of the De novo drug discovery process. Ithelps for the identification of drugs to the rare diseases as well as in the pandemic situationwithin short span of time in a cost-effective way. The underlying principle of drug repurposing is that most of the drugs identified on a primary purpose have shown to treat other diseases also. One such example is Tocilizumab is primarily used for rheumatoid arthritis and it is repurposed to treat cancer and COVID-19. At present, nearly30 % of the FDA approved drugs to treat various diseases are repurposed drugs. The drug repurposing is either drug-centric or disease centric and can be studied by using both experimental and <em>in silico</em> studies. The <em>in silico</em> repurpose drug discovery process is more efficient as it screens thousands of compounds from the diverse libraries within few days by various computational methods like Virtual screening, Docking, MD simulations,Machine Learning, Artificial Intelligence, Genome Wide Association Studies (GWAS), etc. with certain limitations.These limitationscan be addressed by effective integration of advanced technologies to identify a novel multi-purpose drug.</p> ER -